PURCHASE, N.Y., Sept. 23 Nutrition 21, Inc.(Nasdaq: NXXI), the developer and marketer of nutritional supplements underthe Iceland Health(R) and Diabetes Essentials(R) brands, reported today thatresults of a randomized, double-blind, placebo-controlled clinical studypublished online in Diabetes Technology & Therapeutics showed that Nutrition21's Chromax(R) chromium picolinate significantly reduced hunger levels by24%, food intake by 25%, and also reduced cravings for high-fat foods in adultnon-diabetic overweight women. The study was conducted by researchers at thePennington Biomedical Research Center, the largest academically basednutrition research center in the world.
"Study subjects were allowed to eat any type and amount of food throughoutthe study. The participants who received chromium picolinate reduced theircaloric intake by an average of 365 calories per day between their baselineand final (week 8) visit," stated Dr. Steve Anton, investigator and leadauthor of the publication. "Not only are these results clinicallysignificant, it is also noteworthy that participants receiving chromiumpicolinate did not report increased hunger levels despite significantlyreducing their food intake."
James Komorowski, M.S., vice president -- technical services andscientific affairs for Nutrition 21, stated, "These results show that Chromaxchromium picolinate can be useful for overweight individuals desiring toreduce their food intake. The published study also provides clinicalsubstantiation for reduced hunger and reduced cravings claims for food andsupplement manufacturing companies that use Chromax in their formulations."
The randomized, double-blind, placebo-controlled, 8-week study, entitled"Effects of Chromium Picolinate on Food Intake and Satiety," was publishedonline in Diabetes Technology & Therapeutics(http://www.liebertonline.com/dia), and is scheduled to be released in theOctober 2008 print issue of the journal. The study population comprised 42overweight adult women who reported craving carbohydrates. Subjects wereadministered either Chromax chromium picolinate capsules (containing 1,000 mcgchromium) or matching placebo capsules for 8 weeks. Food intake was directlymeasured at the research center's eating laboratory at baseline, after 1 weekand again after 8 weeks.
Michael A. Zeher, president and chief executive officer of Nutrition 21,commented, "The results of this study provide substantial evidence of theefficacy of Chromax in decreasing hunger and high-fat cravings. We arepleased that a renowned research center the caliber of the PenningtonBiomedical Research Center, has completed independent research that validatesthe potential benefits of using Chromax on food intake and satiety levels.This new use can easily be incorporated within the framework of a sensibleweight loss program. With a patent covering the use of chromium for reducingfood cravings and appetite, Nutrition 21 is, again, in the right place, at theright time with safe and effective science-based products for our customersand consumers seeking solutions to their health care needs."
About Pennington Biomedical Research Center
The Pennington Biomedical Research Center mission is to promote healthierlives through research and education in nutrition and preventive medicine.The Center is a campus of the Louisiana State University System and conductsbasic, clinical and population research. The research enterprise at theCenter includes 80 faculty and more than 40 post-doctoral fellows who comprisea network of 50 laboratories supported by lab technicians, nurses, dieticians,and support personnel, and 19 highly specialized core service facilities. TheCenter's nearly 600 employees occupy several buildings on the 234-acre campus.
About Nutrition 21
Nutrition 21, Inc. (Nasdaq: NXXI), headquartered in Purchase, NY, is anutritional bio